In this article, we will list the 5 Most Promising Long-Term Stocks to Buy According to Analysts. Please visit 10 Most Promising Long-Term Stocks to Buy According to Analysts to see the extended list and the methodology behind it.
5. Uber Technologies Inc. (NYSE:UBER)
Average Upside Potential: 49.36%
Uber Technologies Inc. (NYSE:UBER) is one of the most promising long-term stocks to buy according to analysts. On June 18, Life360 (NASDAQ:LIF) and Uber announced a partnership that integrates Uber Family ride services directly into the Life360 app. This collaboration allows parents to request, track, and coordinate rides for teens and other family members within a single interface, aiming to reduce the logistical friction of managing family schedules and transportation.
The integration enables parents to request rides directly to a family member’s current location, with trip progress visible on the Life360 map alongside other location-sharing features. By combining Life360’s coordination tools with Uber Technologies Inc.’s (NYSE:UBER) safety-focused teen accounts, which feature vetted drivers and real-time monitoring, the partnership provides families with increased visibility and peace of mind during travel.
This feature supports Life360’s evolution into a comprehensive family “super app.” The initiative addresses the coordination challenges modern families face, specifically regarding teen independence during busy periods like summer break, by streamlining the connection between location tracking and ride-hailing services.
Uber Technologies Inc. (NYSE:UBER) is a global transportation technology company that focuses on ride-hailing, courier services, food delivery, and freight transport.
4. BeOne Medicines AG (NASDAQ:ONC)
Average Upside Potential: 52.88%
BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne presented new clinical data at the 2026 ASCO Annual Meeting, highlighting accelerated progress across three high-priority solid tumor development programs. The data validates the company’s strategy of pairing specific biological targets with advanced modalities, supporting the advancement of several assets toward pivotal clinical trials throughout 2026.
Key updates include promising efficacy for the CDK4 inhibitor BGB-43395 in first-line metastatic breast cancer, which will move into a Phase 3 trial this month. Additionally, the B7-H4 ADC, BG-C9074, showed encouraging results in ovarian cancer, while the GPC3x4-1BB bispecific antibody, BGB-B2033, demonstrated significant anti-tumor activity in heavily pre-treated hepatocellular carcinoma/HCC.
These findings reflect a major inflection point for BeOne Medicines’ (NASDAQ:ONC) oncology portfolio as it aims to establish new standards of care in breast, gynecologic, and gastrointestinal cancers. The company plans to leverage these results to support upcoming readouts at future medical congresses and continue its rapid development of these differentiated therapeutic candidates.
BeOne Medicines (NASDAQ:ONC) is a global oncology company that discovers and develops innovative treatments that are more affordable and accessible to cancer patients worldwide.
3. Agnico Eagle Mines Limited (NYSE:AEM)
Average Upside Potential: 53.61%
Agnico Eagle Mines Limited (NYSE:AEM) is one of the most promising long-term stocks to buy according to analysts. On June 16, Agnico Eagle Mines completed its acquisition of Rupert Resources Ltd. through a plan of arrangement. Under the terms of the transaction, Rupert shareholders will receive 0.0401 of an Agnico Eagle common share for each Rupert share owned, along with a contingent value right/CVR that provides up to C$3.00 in cash if specific milestones are achieved over the next decade.
As a result of the acquisition, Rupert Resources shares are expected to be delisted from the Toronto Stock Exchange and the OTCQX, and the company will transition to being a non-reporting issuer. Registered shareholders must submit a Letter of Transmittal to Computershare to receive their consideration, while non-registered holders will have their shares handled automatically through their intermediaries.
The CVRs represent a novel listing on the TSX under the symbol “AEM.CV,” with trading expected to commence on June 18. To ensure transparency, Agnico Eagle Mines Limited (NYSE:AEM) committed to quarterly reporting on material developments regarding the acquired mining properties and annual disclosure of gold mineral reserves, supported by the TSX’s Sandbox program for innovative financial instruments.
Agnico Eagle Mines Limited (NYSE:AEM) is a senior Canadian gold mining company and the world’s second-largest gold producer, focused on exploring, developing, and operating mines. Founded in 1957, it operates high-quality, low-risk assets primarily in Canada, Australia, Finland, and Mexico, with about 85% of its production coming from Canada.
2. Zscaler Inc. (NASDAQ:ZS)
Average Upside Potential: 56.19%
Zscaler Inc. (NASDAQ:ZS) is one of the most promising long-term stocks to buy according to analysts. On June 9, Zscaler expanded its Project AI-Guardian initiative by integrating its Zero Trust Exchange and AI Protect portfolio with a broad ecosystem of technology partners. This collaboration aims to provide a unified security framework for enterprise AI, allowing different platforms to share identity context and security signals to eliminate the blind spots often created by fragmented point products.
The platform uses the AI Access Graph and real-time data inspection to monitor and secure AI interactions, from generative AI applications to autonomous agentic workflows. By integrating with partners like AWS, Google Cloud, OpenAI, Databricks, and CoreWeave, Zscaler Inc. (NASDAQ:ZS) enables enterprises to enforce granular zero-trust policies, prevent data leakage, and maintain continuous visibility across their entire AI footprint.
This expanded alliance includes both technology providers and global system integrators, offering pre-validated integrations designed to simplify deployment. The initiative is intended to help organizations accelerate their AI adoption by providing a security-first control plane that protects sensitive intellectual property and infrastructure while ensuring compliance with risk management frameworks.
Zscaler Inc. (NASDAQ:ZS) is a cloud-based internet security platform provider. The company is located in San Jose, California and was founded in September 2007 by Jay Chaudhry and K. Kailash.
1. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Average Upside Potential: 56.96%
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most promising long-term stocks to buy according to analysts. On June 3, Alnylam and Inceptive Nucleics, which builds foundation models of life, announced a collaboration valued at up to $2 billion to accelerate the discovery of RNAi therapeutics. It combines Alnylam’s extensive RNAi platform and two decades of proprietary data with Inceptive’s foundation models and AI expertise. By using GenAI to move beyond traditional trial-and-error drug design, the alliance aims to unlock innovative oligonucleotide designs and improve experimental productivity.
The collaboration will focus on modeling target mRNAs and exploring novel chemical modifications to enhance the potency and efficacy of siRNA molecules. By integrating Inceptive’s AI capabilities, led by Transformer architecture co-inventor Jakob Uszkoreit, into its R&D engine, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) intends to shorten discovery timelines and identify top-performing therapeutic candidates more efficiently, supporting its “Alnylam 2030” pipeline expansion strategy.
Under the terms of the agreement, Inceptive will receive $30 million in upfront consideration, consisting of cash and equity, with the potential for further payments contingent upon reaching preclinical, regulatory, and commercial milestones. This alliance represents a significant step in applying frontier AI to sequence-based medicine, aiming to fundamentally reinvent how RNA therapeutics are designed and developed.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotechnology company that develops therapeutics based on ribonucleic acid interference. The company currently has a range of products in Phase 3, Phase 2, and Phase 1 trials.
While we acknowledge the potential of ALNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best US Stocks to Buy and Hold for the Next 5 Years and 10 Best Up and Coming Stocks to Buy for the Next 3 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
